Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

WEIGHT-LOSS drugs can be a silver bullet for some trying to shed the pounds after years of failure with fad diets and exercise routines. But dodgy vendors selling potentially deadly fake jabs ...

For dividend-seeking investors, a buoyant stock market can be a little annoying. Stock prices rising faster than profits ...

Flush with Trump connections, Ballard Partners is D.C.’s new lobbying powerhouse — and its clients are reaping the benefits.

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Some would say Eli Lilly just had its Novo Nordisk moment. Analysts mostly agree that the selloff in Lilly shares after the ...

Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s sustained over time, a new study found.

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short ...

Baron Capital’s Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...